Abstract: A polypeptide for use in medicine is provided. The polypeptide is administered simultaneously, separately or sequentially with an immune checkpoint inhibitor. The polypeptide comprises at least one polypeptide comprising a region of at least 12 amino acids of a self-antigen or a sequence having at least 80% identity to the region. The polypeptide is less than 100 amino acids in length.

Abstract: A polypeptide for use in medicine is provided. The polypeptide is administered simultaneously, separately or sequentially with an immune checkpoint inhibitor. The polypeptide comprises at least one polypeptide comprising a region of at least 12 amino acids of a self-antigen or a sequence having at least 80% identity to the region. The polypeptide is less than 100 amino acids in length.

Abstract: A polypeptide for use in medicine is provided. The polypeptide is administered simultaneously, separately or sequentially with an immune checkpoint inhibitor. The polypeptide comprises at least one polypeptide comprising a region of at least 12 amino acids of a self-antigen or a sequence having at least 80% identity to the region. The polypeptide is less than 100 amino acids in length.

Abstract: The present invention relates to methods for the identification of a sentinel lymph node and to compounds and preparations used in said methods.

Abstract: The present invention relates to methods for the identification of a sentinel lymph node and to compounds and preparations used in said methods.

Abstract: Ultrasound contrast agents comprising microbubbles of biocompatible gas, e.g. a sulphur halide or a perfluorocarbon, stabilized by opsonisable amphiphilic material, e.g. a membrane-forming lipid such as a phospholipid, especially a negatively charged phospholipid such as a phosphatidylserine, may exhibit prolonged contrast-generating residence time in the liver following intravenous administration.

Abstract: The present invention relates to a method of processing ultrasound images from a subject preadministered with an ultrasound contrast agent wherein quantitative measures of the contrast enhancement pattern of said lymph nodes are generated. The lymphatic system is made of vessels or ducts that begin in tissues and are designed to carry lymph fluid to local lymph nodes where the fluid is filtered and processed and sent to the next lymph node down the line until the fluid reaches the thoracic duct where it enters the blood stream. Lymph fluid which enters the lymph vessels carries with it substances and materials from the tissue, e.g. antigens, particles and cells. The lymph nodes process the lymph fluid by sieving it and macrophages inside the nodes remove particulate and cell material carried by the lymph fluid via phagocytosis.

Abstract: The present invention relates methods for the identification of a sentinel lymph node and to compounds and preparations used in said methods.

Abstract: Radioactive sources, preferably radioactive seeds, for use in brachytherapy comprising a radioisotope within a sealed biocompatible container, wherein at least one part of the outer surface of the container is grooved, preferably with a curved groove. The grooved outer surface is preferably substantially free from angularities. Such grooves enhance the echogenicity of the source using medical ultrasound at a greater range of angles to the ultrasound probe, thus enhancing the ultrasound visibility of the source. Preferred radioisotopes are palladium-103 and iodine-125.

Abstract: Prostate abnormalities such as cancer may be detected by ultrasonic determination of the in-flow kinetics of contrast agent-containing blood in the prostate and/or by observation of disease-related asymmetries in the the spoke-like vascular pattern of the prostate.

Abstract: Medical devices, wherein at least one part of the outer surface of the container is grooved, preferably with a curved groove are disclosed. The grooved outer surface is preferably substantially free from angularities. Such grooves enhance the echogenicity of the device using medical ultrasound at a greater range of angles to the ultrasound probe, thus enhancing the ultrasound visibility of the device.

Abstract: Radioactive sources, preferably radioactive seeds, for use in brachytherapy comprising a radioisotope within a sealed biocompatible container, wherein at least one part of the outer surface of the container is grooved, preferably with a curved groove. The grooved outer surface is preferably substantially free from angularities. Such grooves enhance the echogenicity of the source using medical ultrasound at a greater range of angles to the ultrasound probe, thus enhancing the ultrasound visibility of the source. Preferred radioisotopes are palladium-103 and iodine-125.

Abstract: Ultrasound imaging using gas microbubble-containing contrast agents may be performed in the recirculating phase following admixture of the contrast agent with the blood pool, thereby prolonging the useful imaging time window compared to that conventionally obtained during the backscatter signal peak resulting from first pass of a contrast agent bolus. The length of the time window may further be increased by imaging at ultrasound frequencies of 2 MHz or less, particularly by harmonic imaging at transmit frequencies less than the resonance frequencies of the gas microbubbles.

Abstract: Prostate abnormalities such as cancer may be detected by ultrasonic determination of the in-flow kinetics of contrast agent-containing blood in the prostate and/or by observation of disease-related asymmetries in the the spoke-like vascular pattern of the prostate.

Abstract: Ultrasound contrast agents comprising microbubbles of biocompatible gas, e.g. a sulphur halide or a perfluorocarbon, stabilized by opsonisable amphiphilic material, e.g. a membrane-forming lipid such as a phospholipid, especially a negatively charged phospholipid such as a phosphatidylserine, may exhibit prolonged contrast-generating residence time in the liver following intravenous administration.

Abstract: Prostate abnormalities such as cancer may be detected by ultrasonic determination of the in-flow kinetics of contrast agent-containing blood in the prostate and/or by observation of disease-related asymmetries in the spoke-like vascular pattern of the prostate.